Format

Send to:

Choose Destination
See comment in PubMed Commons below
Rev Urol. 2009 Spring;11(2):52-60.

Effective testosterone suppression for prostate cancer: is there a best castration therapy?

Author information

  • 1Department of Urology, Kimmel Cancer Center, Thomas Jefferson University Philadelphia, PA.

Abstract

Achieving and maintaining effective suppression of serum testosterone levels in men treated with androgen ablation is one of the essential strategies in the management of prostate cancer. Historically, a serum testosterone below 50 ng/dL was considered to be the castrate level. Current data suggest that the new target for either surgical or chemical castration is a serum testosterone level of lower than 20 ng/dL in an attempt to maximize therapeutic outcomes. Testosterone breakthrough and the acute-on-chronic effects of administration of a luteinizing hormone-releasing hormone analogue may cause testosterone levels to periodically rise, sometimes to noncastrate levels. The goal of androgen ablation is to identify those agents that will most consistently achieve and maintain the lowest testosterone levels possible.

KEYWORDS:

Androgen ablation; LHRH analogues; LHRH antagonists; Prostate cancer; Testosterone

PMID:
19680526
[PubMed]
PMCID:
PMC2725306
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for PubMed Central
    Loading ...
    Write to the Help Desk